Moderna Rebrands Cancer Vaccines to Avoid Political Backlash

Moderna is shifting its strategic focus and terminology as it navigates a challenging regulatory environment in the United States. The biotechnology company, known for its COVID-19 vaccines, is transitioning toward personalized cancer treatments while curbing investments in new late-stage vaccine trials for infectious diseases.

This strategic pivot comes amid growing opposition to immunizations from U.S. Officials. On January 22, 2026, Moderna’s CEO informed Bloomberg that the company is curbing investments in vaccine trials due to this backlash. The company does not plan to invest in new late-stage vaccine trials for infections because of the current political climate and skepticism from government officials.

The Transition to Individualized Neoantigen Therapy

As part of this shift, Moderna has rebranded its cancer research. While the technology is mechanistically similar to a vaccine, the company has avoided the term vaccine in formal communications and regulatory filings since 2023. Instead, it uses the term individualized neoantigen therapy (INT).

The technical process involves sequencing a patient’s cancer cells to identify specific molecules on their surface called neoantigens. Moderna then packages the genetic code for these molecules into a shot, which instructs the patient’s immune system to target and kill cells displaying those specific markers.

The rebranding is intended to better describe the program’s goal, as the treatment is administered to patients who already have cancer, making it a therapy rather than a preventive measure. However, the shift also serves to distance the innovation from vaccine-related fearmongering fueled by high-ranking U.S. Officials.

Clinical Results and Partnerships

Moderna’s oncology efforts are being conducted in partnership with Merck & Co. In a $250 million deal, Merck took up an option on the personalized RNA-based cancer vaccine. The collaboration focuses on an experimental treatment known as intismeran autogene (mRNA-4157 or V940).

Recent data from a Phase 2 trial involving 157 patients with stage 3 or stage 4 melanoma indicates significant efficacy. The trial found that customized mRNA vaccines, when used alongside the immunotherapy drug Keytruda (pembrolizumab), appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over a five-year follow-up period compared to standard treatment alone.

Keytruda works by blocking PD-1 receptors on T cells, preventing cancer cells from shutting down the immune response. The addition of the personalized mRNA therapy further directs the immune system to attack the specific neoantigens of the patient’s tumor.

Regulatory and Political Pressure

The shift in Moderna’s focus is closely tied to actions taken by the Department of Health and Human Services under Robert F. Kennedy Jr. The agency has unwound support for numerous mRNA projects, including the cancellation of a $776 million award to Moderna for a bird flu vaccine.

This environment has led to a linguistic shift in scientific reporting. In a paper published in February 2026, the main text did not use the word vaccine at all, with the term appearing only in the footnotes within the titles of older patents and papers.

Vaccines are maybe a dirty word nowadays, but we still believe in the science and harnessing our immune system to not only fight infections, but hopefully to also fight … cancers

Kyle Holen, head of Moderna’s cancer program

Medical Community Reaction

The decision to rename the treatment has drawn criticism from some medical professionals. Ryan Sullivan, a physician at Massachusetts General Hospital, expressed concern that the change in terminology might affect whether trial volunteers are properly informed, noting that some patients might decline treatment if they believe We see a vaccine.

Conversely, other experts believe the nomenclature shift is a necessary compromise. Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre in Toronto, suggested the name change is acceptable if it allows critical research to continue despite political opposition.

A Phase 3 trial for the cancer therapy is currently underway, and enrollment for that study has been completed.